Results 51 to 60 of about 67,104 (261)

Evaluation of a PACAP Peptide Analogue Labeled with (68)Ga Using Two Different Chelating Agents. [PDF]

open access: yes, 2016
OBJECTIVE: The authors have conjugated chelating agents (DOTA and NODAGA) with a peptide (pituitary adenylate cyclase-activating peptide [PACAP] analogue) that has a high affinity for VPAC1 receptors expressed on cancer cells.
Chen, Chang-Po   +6 more
core   +2 more sources

RADIONUCLIDE IMAGING AND THERAPY OF NEUROENDOCRINE TUMOURS

open access: yesJournal of Cancer and Allied Specialties, 2015
The incidence and prevalence of neuroendocrine tumours (NETs) are on the rise. Although NETs are a heterogeneous group of tumours, they have some similar properties, for example, that they can concentrate neuroamines and tend to have a high degree of ...
Shaunak Navalkissoor   +1 more
doaj   +1 more source

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review

open access: yesFrontiers in Chemistry, 2023
Copper has several clinically relevant radioisotopes and versatile coordination chemistry, allowing attachment of its radionuclides to biological molecules.
Mazhar Hussain   +5 more
doaj   +1 more source

Radioisotopic purity and imaging properties of cyclotron-produced 99mTc using direct 100Mo(p,2n) reaction [PDF]

open access: yes, 2018
Evaluation of the radioisotopic purity of technetium-99m (99mTc) produced in GBq amounts by proton bombardment of enriched molibdenum-100 (100Mo) metallic targets at low proton energies (i.e. within 15\u201320 MeV) is conducted.
Bello, M.   +24 more
core   +2 more sources

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years

open access: yesWorld Journal of Nuclear Medicine, 2020
In recent years, lutetium-177 (177Lu)-labeled prostate-specific membrane antigen (PSMA)-617 has become a promising new therapeutic agent in patients with metastatic castration-resistant prostate cancer (mCRPC).
Majid Assadi   +9 more
doaj   +1 more source

Assessment of poststress left ventricular ejection fraction by gated SPECT: comparison with equilibrium radionuclide angiocardiography [PDF]

open access: yes, 2010
PURPOSE: We compared left ventricular (LV) ejection fraction obtained by gated SPECT with that obtained by equilibrium radionuclide angiocardiography in a large cohort of patients.
ACAMPA, WANDA   +8 more
core  

Excitation functions of proton induced nuclear reactions on natW up to 40 MeV [PDF]

open access: yes, 2007
Excitation functions for the production of the 181,182m,182g,183,184g,186Re and 183,184Ta radionuclides from proton bombardment on natural tungsten were measured using the stacked-foil activation technique for the proton energies up to 40 MeV. A new data
Akkermans   +40 more
core   +2 more sources

Progress and Prospects of Persistent Luminescent Nanocrystals in Biomedical Applications

open access: yesAdvanced Optical Materials, EarlyView.
This review summarizes recent progress in materials‐level control of persistent luminescence, including mechanistic understanding, wavelength/intensity tuning, and activation strategies, as well as emerging biomedical applications in imaging, biosensing, cell tracking, optogenetic stimulation, and biophotochemical activation.
Peng Pei   +5 more
wiley   +1 more source

Comparison of technetium-99m IgG with technetium-99m red blood cells labeling in cardiac blood-pool scintigraphy: A preliminary study [PDF]

open access: yes, 2011
This first clinical prospective study was conducted to use of technetium-99m immunoglobulin G (99mTc-IgG) as compared with autologous 99mTc-red blood cells (RBC) in gated blood pool ventriculography.
Amini, A.   +7 more
core  

First-in-man evaluation of 124I-PGN650: A PET tracer for detecting phosphatidylserine as a biomarker of the solid tumor microenvironment [PDF]

open access: yes, 2017
Purpose: PGN650 is a F(ab′) 2 antibody fragment that targets phosphatidylserine (PS), a marker normally absent that becomes exposed on tumor cells and tumor vasculature in response to oxidative stress and increases in response to therapy.
Dehdashti, Farrokh   +9 more
core   +2 more sources

Home - About - Disclaimer - Privacy